Results 131 to 140 of about 192,797 (347)
Clinical Pharmacology in Drug Development, EarlyView.Abstract Mocravimod, a novel immunomodulator targeting sphingosine‐1‐phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism.
Dymphy R. Huntjens +2 more
wiley +1 more source
Are Women In Lomé Getting Their Desired Methods Of Contraception? Understanding Provider Bias From Restrictions To Choice. [PDF]
, 2019 Background: Despite improvements in contraception availability, women face persistent barriers that compromise reproductive autonomy and informed choice.
Koffi, Tekou +4 more
core
Clinical Pharmacology &Therapeutics, EarlyView.Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott +7 more
wiley +1 more source
URGENCY OF COMBINED ORAL CONTRACEPTIVES IN PROLONGED REGIMEN USE
Акушерство, гинекология и репродукция, 2016 This article presents the issues on combined oral contraceptives use in prolonged regimen.
A. L. Tikhomirov, A. A. Ledenkova
doaj
Contraceptive Use in the United States [PDF]
, 2016 WHO NEEDS CONTRACEPTIVES?There are 61 million U.S. women in their childbearing years (15–44). About 43 million of them (70%) are at risk of unintended pregnancy—that is, they are sexually active and do not want to become pregnant, but could become ...
core
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Postabortal rehabilitation – aspects of the problem: possibilities of combined oral contraceptives
Гинекология, 2013 The article presents modern concepts of pharmacological possibilities to use combined oral contraceptives for prevention of various postabortal complications, rational approaches of their use in female patients in postabortal period.
M B Khamoshina +4 more
doaj
Benefits of using combined oral contraceptive with drospirenone in 24+4 overweight adolescents [PDF]
Гинекология, 2014 Combined oral contraception is known as a reliable method of birth control that can provide additional benefits to health and quality of life . Reliability and the main characteristics of combined oral contraceptives do not differ significantly.
I V Kuznetsova, P A Nabiyeva
doaj
ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Combined oral contraceptives: evolution of the relationship benefit/risk
Безопасность и риск фармакотерапии, 2018 Currently, more than 100 million women worldwide use combined oral contraceptives. Risk/benefit ratio of this group of drugs over the half-century history is largely changed in the direction of safety.
O. S. Alyautdina
doaj